Removal of pro-inflammatory cytokines with renal replacement therapy: Sense or nonsense?

Intensive Care Medicine

Volumn 21, Issue 2, 1995, Pages 169-176

  Schetz, M ^a   Ferdinande, P ^a   Van den Berghe, G ^a   Verwaest, C ^a   Lauwers, P ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1; TUMOR NECROSIS FACTOR;

DIALYSIS MEMBRANE; HEMODIALYSIS; HEMOFILTRATION; HUMAN; MULTIPLE ORGAN FAILURE; REVIEW; SEPSIS;

ANIMAL; CYTOKINES; HUMAN; INFLAMMATION MEDIATORS; MEMBRANES, ARTIFICIAL; MULTIPLE ORGAN FAILURE; RENAL REPLACEMENT THERAPY; SEPSIS;

EID: 0028903973     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/BF01726541     Document Type: Review

References (77)

1. The pathogenesis of sepsis
2. Serum cytokine levels in human septic shock — Relation to multiple-system organ failure and mortality
3. Hemofiltration in septic ARDS. The artificial kidney as an artificial endocrine lung
4. Use of extra-corporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients
5. Acute respiratory failure after cardiac surgery: clinical experience with the application of continuous arteriovenous hemofiltration
6. Continuous arteriovenous hemofiltration and respiratory function in multiple organ systems failure
7. Continuous arteriovenous hemofiltration/dialysis improves pulmonary gas exchange in children with multiple organ system failure
8. Comparison of pumpdriven and spontaneous continuous hemofiltration in postoperative acute renal failure
9. Can hemodiafiltration increase survival in acute endotoxemia—a porcine shock model
10. Hemofiltration reverses left ventricular dysfunction during sepsis in dogs
11. Influence of continuous hemofiltration on hemodynamics and central blood volume in experimental endotoxic shock
12. The consequences of continuous hemofiltration on lung mechanics and extravascular lung water in a porcine endotoxic shock model
13. High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig
14. The orchestra of mediators in the pathogenesis of septic shock: a review
15. The biologic characteristics of cytokines and their implication in surgical injury
16. Endotoxin, tumor necrosis factor, and related mediators: new approaches to shock
17. Cytokines and sepsis: pathophysiology and therapy
18. Tumor necrosis factor: an updated review of its biology
19. The role of interleukin-1 in septic shock
20. Anticytokine therapies in sepsis
21. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome
22. Drug removal during high efficiency and high-flux hemodialysis
23. Drug clearance by continuous haemodiafiltration (CAVHD). Analysis of sieving coefficient and mass transfer coefficients of diffusion
24. Drug therapy in patients undergoing hemodialysis: clinical pharmacokinetic considerations
25. Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations
26. Cachectin/tumor necrosis factor: production, distribution and metabolic fate in vivo
27. Cytokine appearance in human endotoxemia and primate bacteremia
28. Detection of circulating tumor necrosis factor after endotoxin administration
29. Circulating Interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever
30. Endotoxin administration to humans: a model of inflammatory responses relevant to sepsis
31. The complex pattern of cytokines in sepsis
32. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans
33. Plasma tumor necrosis factor levels in patients with presumed sepsis
34. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlated with infection and mortality
35. Serum tumor necrosis factor levels in patients with infections disease and septic shock
36. Dissociation between plasma and monocyte-associated cytokines during sepsis
37. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor and acute-phase proteins during the treatment of severe sepsis in humans
38. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α and interferon-γ in the serum of patients with septic shock
39. Plasma tumor necrosis factor and mortality in critically ill septic patients
40. Human tumor necrosis factor: production, purification and characterization
41. The active form of tumor necrosis factor is a trimer
42. Binding of tumor necrosis factor alpha to activated forms of human plasma alpha 2 macroglobulin
43. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis facxtor α in vitro and in vivo
44. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in human
45. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications of the complex physiology of TNF
46. Tumor necrosis factor and regulation of metabolism in infection: role of systemic versus tissue level
47. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia
48. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production
49. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans
50. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer
51. Phase I study of recombinant tumor necrosis factor in cancer patients
52. Cytokine serum level during severe sepsis: human IL-6 as a marker of severity
53. The complex pattern of cytokines in serum from patients with meningococcal septic shock: Association between interleukin-6, interleukin-1 and fatal outcome
54. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura
55. Identification of α 2 macroglobulin cytokine binding plasma protein. Binding of interleukin 1 β α 2 macroglobulin
56. Blocking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro
57. Prostaglandin E-2 regulates macrophage derived tumor necrosis factor gene expression
58. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance
59. Correlations and interactions in the production of interleukin-6 (IL-6), interleukin-1 (IL-1) and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF
60. Removal of interleukin-1β and tumor necrosis factor from human plasma by in vitro dialysis with polyacrylonitrile membranes
61. Studies on the ability of hemodialysis membranes to induce, bind and clear human interleukin-1
62. Removal of cytokines by hemodialysis membrane in vitro
63. Interleukin-1 and its relevance in patients treated with hemodialysis
64. Production of cytokines in hemodialysis
65. Hemodialysis-associated induction of cytokines
66. Induction of cytokines by dialysis membranes in normal whole blood: a new in vitro assay for evaluating membrane biocompatibility
67. High-permeable membranes and hypersensitivity-like reactions: role of dialysis fluid contamination
68. Removal of endotoxin and cytokines by adsorbents and the effect of plasma protein binding
69. Increased plasma tumor necrosis factor concentration in severe rhabdomyolysis is not reduced by continuous arteriovenous hemodialysis
70. Elimination of tumor necrosis factor α (TNFα) by continuous venovenous hemofiltration
71. Transmembrane flux of IL-1β and TNFα in patients undergoing continuous arteriovenous hemodialysis
72. Tumor necrosis factor clearance during veno-venolus hemodiafiltration in the critically ill
73. In vivo catecholamine extraction during continuous hemodiafiltration in inotrope-dependent patients
74. Origin of myocardial depressant factor in shock
75. A circulating myocardial depressant substance in humans with septic shock: Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance
76. A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock
77. Removal of circulating tumor necrosis factor. Its role in septic shock treatment